Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-731-8180
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees117
Next Earnings Date7/29/2019 (Estimated)
OptionableNot Optionable
Odonate Therapeutics (NASDAQ:ODT) Frequently Asked Questions
What is Odonate Therapeutics' stock symbol?
Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."
How were Odonate Therapeutics' earnings last quarter?
Odonate Therapeutics Inc (NASDAQ:ODT) posted its quarterly earnings data on Thursday, April, 25th. The company reported ($1.16) EPS for the quarter, topping the consensus estimate of ($1.24) by $0.08. View Odonate Therapeutics' Earnings History.
When is Odonate Therapeutics' next earnings date?
What is the consensus analysts' recommendation for Odonate Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Odonate Therapeutics.
What are Wall Street analysts saying about Odonate Therapeutics stock?
Here are some recent quotes from research analysts about Odonate Therapeutics stock:
- 1. According to Zacks Investment Research, "Odonate Therapeutics, LLC is a pharmaceutical company. It engaged in the development of therapeutics to improve and extend the lives of patients with cancer. The company focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer. Odonate Therapeutics, LLC is based in SAN DIEGO, United States. " (4/30/2019)
- 2. Cowen Inc analysts commented, "We believe current valuation is a compelling entry point for investors and we expect the stock should begin to work in anticipation of these results with shares reaching ~$40, if data are positive." (2/22/2019)
Has Odonate Therapeutics been receiving favorable news coverage?
News articles about ODT stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Odonate Therapeutics earned a daily sentiment score of 1.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of Odonate Therapeutics' key competitors?
Some companies that are related to Odonate Therapeutics include Uniqure (QURE), Myokardia (MYOK), PTC Therapeutics (PTCT), Emergent Biosolutions (EBS), Ligand Pharmaceuticals (LGND), Insmed (INSM), Portola Pharmaceuticals (PTLA), Endocyte (ECYT), Xencor (XNCR), AnaptysBio (ANAB), Allakos (ALLK), Akcea Therapeutics (AKCA), Arrowhead Pharmaceuticals (ARWR), Pacira Biosciences (PCRX) and Enanta Pharmaceuticals (ENTA).
What other stocks do shareholders of Odonate Therapeutics own?
Who are Odonate Therapeutics' key executives?
Odonate Therapeutics' management team includes the folowing people:
- Mr. Kevin C. Tang, Chairman & CEO (Age 52)
- Mr. John G. Lemkey, Chief Operating Officer (Age 38)
- Dr. Joseph P. O'Connell M.D., Chief Medical Officer (Age 65)
- Mr. Michael S. Hearne, CFO & Principal Accounting Officer (Age 57)
- Dr. Steven S. Pfeiffer Ph.D., VP of Technical Operations (Age 43)
When did Odonate Therapeutics IPO?
(ODT) raised $150 million in an initial public offering on Thursday, December 7th 2017. The company issued 5,900,000 shares at $24.00-$27.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Cowen was co-manager.
Who are Odonate Therapeutics' major shareholders?
Odonate Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Tang Capital Management LLC (48.93%), Janus Henderson Group PLC (4.79%), Redmile Group LLC (1.78%), FMR LLC (1.56%), BlackRock Inc. (1.39%) and Opaleye Management Inc. (1.22%). Company insiders that own Odonate Therapeutics stock include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang. View Institutional Ownership Trends for Odonate Therapeutics.
Which major investors are selling Odonate Therapeutics stock?
ODT stock was sold by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Sabby Management LLC, Janus Henderson Group PLC, Oxford Asset Management LLP, FMR LLC, Spark Investment Management LLC and Menta Capital LLC. View Insider Buying and Selling for Odonate Therapeutics.
Which major investors are buying Odonate Therapeutics stock?
ODT stock was acquired by a variety of institutional investors in the last quarter, including Opaleye Management Inc., California Public Employees Retirement System, Morgan Stanley, Jacobs Levy Equity Management Inc., BlackRock Inc., JPMorgan Chase & Co., Redmile Group LLC and Northern Trust Corp. Company insiders that have bought Odonate Therapeutics stock in the last two years include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang. View Insider Buying and Selling for Odonate Therapeutics.
How do I buy shares of Odonate Therapeutics?
Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Odonate Therapeutics' stock price today?
One share of ODT stock can currently be purchased for approximately $22.90.
How big of a company is Odonate Therapeutics?
Odonate Therapeutics has a market capitalization of $612.51 million. The company earns $-88,960,000.00 in net income (profit) each year or ($3.64) on an earnings per share basis. Odonate Therapeutics employs 117 workers across the globe.
What is Odonate Therapeutics' official website?
How can I contact Odonate Therapeutics?
Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]
MarketBeat Community Rating for Odonate Therapeutics (NASDAQ ODT)
MarketBeat's community ratings are surveys of what our community members think about Odonate Therapeutics and other stocks. Vote "Outperform" if you believe ODT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ODT will underperform the S&P 500 over the long term. You may vote once every thirty days.
